New ADR reporting regulations in place in Canada
This article was originally published in SRA
Canada has made changes to its regulations on adverse drug reaction reporting by pharmaceutical companies1,2. The new regulations, which came into effect on 2 March, require manufacturers to notify to the health minister when they identify any significant safety signals in their annual summary reports.
You may also be interested in...
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
The Canadian medtech regulator has recommended updating its list of recognized medical device standards that manufacturers can rely on to demonstrate compliance with local safety, effectiveness and labeling requirements.